Anifrolumab: all 32 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusRecruitingNCT07751848Phase 3
• Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentRecruitingNCT07691970Phase 3
• Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)Not yet recruitingNCT07688980Phase 1
• A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusRecruitingNCT07630714Phase 2
• Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)RecruitingNCT07584083Phase 2
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusRecruitingNCT07430306Phase 3
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruitingNCT06594068Phase 4
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)RecruitingNCT06455449Phase 3
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruitingNCT05835310Phase 3
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingNCT05440422Phase 2
• Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)CompletedNCT04931563Phase 3Results posted
• A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin ManifestationsCompletedNCT02962960Phase 2Results posted
• Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT02794285Phase 3Results posted
• A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy SubjectsCompletedNCT02601625Phase 1Results posted
• Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus NephritisCompletedNCT02547922Phase 2Results posted
• Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT02446912Phase 3Results posted
• Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT02446899Phase 3Results posted
• An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in AdultsCompletedNCT01753193Phase 2Results posted
• Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.CompletedNCT01559090Phase 2Results posted
• A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus ErythematosusCompletedNCT01438489Phase 2Results posted
• Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult ParticipantsCompletedNCT06662123Phase 1
• Anifrolumab for Hidradenitis SuppurativaCompletedNCT06374212Phase 2
• A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusActive, not recruitingNCT06015737Phase 3
• Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active, not recruitingNCT05925803Phase 3
• Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoStatus unknownNCT05917561Phase 2
• Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's SyndromeStatus unknownNCT05383677Phase 2
• Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive, not recruitingNCT05138133Phase 3
• Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)CompletedNCT05001698Phase 1
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusActive, not recruitingNCT04877691Phase 3
• Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLEStatus unknownNCT04726553Early Phase 1
• A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)Status unknownNCT03435601Phase 2
• A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With SclerodermaCompletedNCT00930683Phase 1

← Anifrolumab overview